Pfizer moves global clindamycin manufacture to China with Hisoar
This article was originally published in Scrip
The major Chinese active pharmaceutical ingredients (API) manufacturer Zhejiang Hisoar is aggressively upgrading its capabilities in a move designed to serve a broader range of clients. The firm has signed a 20-year agreement with Pfizer Asia Manufacturing, the Singapore-based API sourcing and manufacturing arm of Pfizer, related to clindamycin, one of its main products.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.